- You can view the full Celldex Therapeutics Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Celldex Therapeutics ( CLDX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 1.3%. By the end of trading, Celldex Therapeutics fell $0.55 (-2.0%) to $27.45 on light volume. Throughout the day, 1,608,065 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 2,195,500 shares. The stock ranged in price between $26.96-$27.86 after having opened the day at $27.47 as compared to the previous trading day's close of $28.00. Other companies within the Health Care sector that declined today were: Durect Corporation ( DRRX), down 20.5%, Dehaier Medical Systems ( DHRM), down 17.0%, Liberator Medical Holdings ( LBMH), down 11.6% and Medicines ( MDCO), down 11.5%. Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $2.1 billion and is part of the drugs industry. Shares are up 15.7% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.
